INFINITY PHARMACEUTICALS INC's ticker is INFI and the CUSIP is 45665G303. A total of 74 filers reported holding INFINITY PHARMACEUTICALS INC in Q2 2017. The put-call ratio across all filers is 0.76 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $13 | -100.0% | 23,700 | -35.2% | 0.00% | – |
Q3 2022 | $43,000 | +95.5% | 36,595 | +91.6% | 0.00% | – |
Q1 2022 | $22,000 | -85.7% | 19,100 | -71.0% | 0.00% | – |
Q4 2021 | $154,000 | -54.2% | 65,800 | -39.0% | 0.00% | – |
Q2 2021 | $336,000 | -11.1% | 107,942 | -13.7% | 0.00% | – |
Q1 2021 | $378,000 | +822.0% | 125,147 | +572.8% | 0.00% | – |
Q4 2020 | $41,000 | -32.8% | 18,600 | -63.6% | 0.00% | – |
Q4 2018 | $61,000 | +3.4% | 51,029 | +136.2% | 0.00% | – |
Q3 2018 | $59,000 | -28.0% | 21,600 | -44.9% | 0.00% | – |
Q2 2018 | $82,000 | 0.0% | 39,210 | 0.0% | 0.00% | – |
Q1 2018 | $82,000 | +26.2% | 39,210 | +22.9% | 0.00% | – |
Q4 2017 | $65,000 | +62.5% | 31,900 | +30.2% | 0.00% | – |
Q2 2017 | $40,000 | -71.4% | 24,500 | -41.7% | 0.00% | – |
Q1 2017 | $140,000 | +211.1% | 42,039 | +26.7% | 0.00% | – |
Q4 2016 | $45,000 | +9.8% | 33,184 | +23.3% | 0.00% | – |
Q3 2016 | $41,000 | +95.2% | 26,903 | +76.3% | 0.00% | – |
Q2 2016 | $21,000 | – | 15,257 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
GREAT POINT PARTNERS LLC | 1,100,000 | $14,762,000 | 6.34% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,882,805 | $52,107,000 | 1.90% |
Cheyne Capital Management (UK) LLP | 326,821 | $4,388,000 | 1.56% |
BB BIOTECH AG | 2,320,737 | $31,144,000 | 1.27% |
Broadfin Capital, LLC | 854,384 | $11,466,000 | 1.20% |
HealthCor Management, L.P. | 1,162,200 | $15,597,000 | 0.80% |
Orbimed Advisors | 4,736,900 | $63,569,000 | 0.66% |
Rhenman & Partners Asset Management AB | 148,000 | $1,986,000 | 0.58% |
SOUND ENERGY PARTNERS, INC. | 51,000 | $684,000 | 0.53% |
Rock Springs Capital Management LP | 210,000 | $2,818,000 | 0.44% |